Formulation CDMO services refer to a contract development and manufacturing organization that provides pharmaceutical formulation development and manufacturing services. It provides pharmaceutical companies and biotechnology companies with a full range of formulation solutions from the drug development stage to the commercial production stage.
The global Formulation CDMO Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Formulation CDMO services usually include the following services: formulation development, technology transfer, preparation of prescriptions, process standards, mass production, quality control and analysis, and registration support. Through the preparation CDMO service, the development and manufacture of preparations can be entrusted to professional institutions, thereby reducing their own R&D and production costs, and can speed up the process of launching products with the help of the experience and facilities of CDMO institutions. At the same time, the preparation CDMO service can also help customers ensure the quality, safety and regulatory compliance of preparation products, and improve the market competitiveness of products.
This report aims to provide a comprehensive presentation of the global market for Formulation CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Formulation CDMO Services.
Report Scope
The Formulation CDMO Services market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Formulation CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Formulation CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Medicilon
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Zhejiang Jiuzhou Pharmaceutical
Sinopep
Frontier Biotechnologies
JYMed
Chengdu Shengnuo Biotechnology
Shanghai Soho-Yiming Pharmaceuticals
Chinese Peptide Company
Ambio Pharmaceuticals
Zhejiang Peptites Biotech
STA Pharmaceutical
Zhejiang Langhua Pharmaceutical
Viva Biotech
Segment by Type
Small Molecule CDMO
Macro-molecular CDMO
Segment by Application
Clinical Application
Commercial Production
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Formulation CDMO Services companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Formulation CDMO Services 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Small Molecule CDMO
1.2.3 Macro-molecular CDMO
1.3 麻豆原创 by Application
1.3.1 Global Formulation CDMO Services 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinical Application
1.3.3 Commercial Production
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Formulation CDMO Services 麻豆原创 Perspective (2019-2030)
2.2 Formulation CDMO Services Growth Trends by Region
2.2.1 Global Formulation CDMO Services 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Formulation CDMO Services Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Formulation CDMO Services Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Formulation CDMO Services 麻豆原创 Dynamics
2.3.1 Formulation CDMO Services Industry Trends
2.3.2 Formulation CDMO Services 麻豆原创 Drivers
2.3.3 Formulation CDMO Services 麻豆原创 Challenges
2.3.4 Formulation CDMO Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Formulation CDMO Services Players by Revenue
3.1.1 Global Top Formulation CDMO Services Players by Revenue (2019-2024)
3.1.2 Global Formulation CDMO Services Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Formulation CDMO Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Formulation CDMO Services Revenue
3.4 Global Formulation CDMO Services 麻豆原创 Concentration Ratio
3.4.1 Global Formulation CDMO Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Formulation CDMO Services Revenue in 2023
3.5 Formulation CDMO Services Key Players Head office and Area Served
3.6 Key Players Formulation CDMO Services Product Solution and Service
3.7 Date of Enter into Formulation CDMO Services 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Formulation CDMO Services Breakdown Data by Type
4.1 Global Formulation CDMO Services Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Formulation CDMO Services Forecasted 麻豆原创 Size by Type (2025-2030)
5 Formulation CDMO Services Breakdown Data by Application
5.1 Global Formulation CDMO Services Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Formulation CDMO Services Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Formulation CDMO Services 麻豆原创 Size (2019-2030)
6.2 North America Formulation CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Formulation CDMO Services 麻豆原创 Size by Country (2019-2024)
6.4 North America Formulation CDMO Services 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Formulation CDMO Services 麻豆原创 Size (2019-2030)
7.2 Europe Formulation CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Formulation CDMO Services 麻豆原创 Size by Country (2019-2024)
7.4 Europe Formulation CDMO Services 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Formulation CDMO Services 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Formulation CDMO Services 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Formulation CDMO Services 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Formulation CDMO Services 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Formulation CDMO Services 麻豆原创 Size (2019-2030)
9.2 Latin America Formulation CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Formulation CDMO Services 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Formulation CDMO Services 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Formulation CDMO Services 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Formulation CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Formulation CDMO Services 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Formulation CDMO Services 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medicilon
11.1.1 Medicilon Company Detail
11.1.2 Medicilon Business Overview
11.1.3 Medicilon Formulation CDMO Services Introduction
11.1.4 Medicilon Revenue in Formulation CDMO Services Business (2019-2024)
11.1.5 Medicilon Recent Development
11.2 Gliead
11.2.1 Gliead Company Detail
11.2.2 Gliead Business Overview
11.2.3 Gliead Formulation CDMO Services Introduction
11.2.4 Gliead Revenue in Formulation CDMO Services Business (2019-2024)
11.2.5 Gliead Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Formulation CDMO Services Introduction
11.3.4 Boehringer Ingelheim Revenue in Formulation CDMO Services Business (2019-2024)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Formulation CDMO Services Introduction
11.4.4 Vertex Revenue in Formulation CDMO Services Business (2019-2024)
11.4.5 Vertex Recent Development
11.5 Mirati Therapeutics
11.5.1 Mirati Therapeutics Company Detail
11.5.2 Mirati Therapeutics Business Overview
11.5.3 Mirati Therapeutics Formulation CDMO Services Introduction
11.5.4 Mirati Therapeutics Revenue in Formulation CDMO Services Business (2019-2024)
11.5.5 Mirati Therapeutics Recent Development
11.6 AMPAC
11.6.1 AMPAC Company Detail
11.6.2 AMPAC Business Overview
11.6.3 AMPAC Formulation CDMO Services Introduction
11.6.4 AMPAC Revenue in Formulation CDMO Services Business (2019-2024)
11.6.5 AMPAC Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Formulation CDMO Services Introduction
11.7.4 Pfizer Revenue in Formulation CDMO Services Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Polypeptide
11.8.1 Polypeptide Company Detail
11.8.2 Polypeptide Business Overview
11.8.3 Polypeptide Formulation CDMO Services Introduction
11.8.4 Polypeptide Revenue in Formulation CDMO Services Business (2019-2024)
11.8.5 Polypeptide Recent Development
11.9 Bachem
11.9.1 Bachem Company Detail
11.9.2 Bachem Business Overview
11.9.3 Bachem Formulation CDMO Services Introduction
11.9.4 Bachem Revenue in Formulation CDMO Services Business (2019-2024)
11.9.5 Bachem Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Formulation CDMO Services Introduction
11.10.4 Merck Revenue in Formulation CDMO Services Business (2019-2024)
11.10.5 Merck Recent Development
11.11 Asymchem
11.11.1 Asymchem Company Detail
11.11.2 Asymchem Business Overview
11.11.3 Asymchem Formulation CDMO Services Introduction
11.11.4 Asymchem Revenue in Formulation CDMO Services Business (2019-2024)
11.11.5 Asymchem Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Detail
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Formulation CDMO Services Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Formulation CDMO Services Business (2019-2024)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
11.13 Sinopep
11.13.1 Sinopep Company Detail
11.13.2 Sinopep Business Overview
11.13.3 Sinopep Formulation CDMO Services Introduction
11.13.4 Sinopep Revenue in Formulation CDMO Services Business (2019-2024)
11.13.5 Sinopep Recent Development
11.14 Frontier Biotechnologies
11.14.1 Frontier Biotechnologies Company Detail
11.14.2 Frontier Biotechnologies Business Overview
11.14.3 Frontier Biotechnologies Formulation CDMO Services Introduction
11.14.4 Frontier Biotechnologies Revenue in Formulation CDMO Services Business (2019-2024)
11.14.5 Frontier Biotechnologies Recent Development
11.15 JYMed
11.15.1 JYMed Company Detail
11.15.2 JYMed Business Overview
11.15.3 JYMed Formulation CDMO Services Introduction
11.15.4 JYMed Revenue in Formulation CDMO Services Business (2019-2024)
11.15.5 JYMed Recent Development
11.16 Chengdu Shengnuo Biotechnology
11.16.1 Chengdu Shengnuo Biotechnology Company Detail
11.16.2 Chengdu Shengnuo Biotechnology Business Overview
11.16.3 Chengdu Shengnuo Biotechnology Formulation CDMO Services Introduction
11.16.4 Chengdu Shengnuo Biotechnology Revenue in Formulation CDMO Services Business (2019-2024)
11.16.5 Chengdu Shengnuo Biotechnology Recent Development
11.17 Shanghai Soho-Yiming Pharmaceuticals
11.17.1 Shanghai Soho-Yiming Pharmaceuticals Company Detail
11.17.2 Shanghai Soho-Yiming Pharmaceuticals Business Overview
11.17.3 Shanghai Soho-Yiming Pharmaceuticals Formulation CDMO Services Introduction
11.17.4 Shanghai Soho-Yiming Pharmaceuticals Revenue in Formulation CDMO Services Business (2019-2024)
11.17.5 Shanghai Soho-Yiming Pharmaceuticals Recent Development
11.18 Chinese Peptide Company
11.18.1 Chinese Peptide Company Company Detail
11.18.2 Chinese Peptide Company Business Overview
11.18.3 Chinese Peptide Company Formulation CDMO Services Introduction
11.18.4 Chinese Peptide Company Revenue in Formulation CDMO Services Business (2019-2024)
11.18.5 Chinese Peptide Company Recent Development
11.19 Ambio Pharmaceuticals
11.19.1 Ambio Pharmaceuticals Company Detail
11.19.2 Ambio Pharmaceuticals Business Overview
11.19.3 Ambio Pharmaceuticals Formulation CDMO Services Introduction
11.19.4 Ambio Pharmaceuticals Revenue in Formulation CDMO Services Business (2019-2024)
11.19.5 Ambio Pharmaceuticals Recent Development
11.20 Zhejiang Peptites Biotech
11.20.1 Zhejiang Peptites Biotech Company Detail
11.20.2 Zhejiang Peptites Biotech Business Overview
11.20.3 Zhejiang Peptites Biotech Formulation CDMO Services Introduction
11.20.4 Zhejiang Peptites Biotech Revenue in Formulation CDMO Services Business (2019-2024)
11.20.5 Zhejiang Peptites Biotech Recent Development
11.21 STA Pharmaceutical
11.21.1 STA Pharmaceutical Company Detail
11.21.2 STA Pharmaceutical Business Overview
11.21.3 STA Pharmaceutical Formulation CDMO Services Introduction
11.21.4 STA Pharmaceutical Revenue in Formulation CDMO Services Business (2019-2024)
11.21.5 STA Pharmaceutical Recent Development
11.22 Zhejiang Langhua Pharmaceutical
11.22.1 Zhejiang Langhua Pharmaceutical Company Detail
11.22.2 Zhejiang Langhua Pharmaceutical Business Overview
11.22.3 Zhejiang Langhua Pharmaceutical Formulation CDMO Services Introduction
11.22.4 Zhejiang Langhua Pharmaceutical Revenue in Formulation CDMO Services Business (2019-2024)
11.22.5 Zhejiang Langhua Pharmaceutical Recent Development
11.23 Viva Biotech
11.23.1 Viva Biotech Company Detail
11.23.2 Viva Biotech Business Overview
11.23.3 Viva Biotech Formulation CDMO Services Introduction
11.23.4 Viva Biotech Revenue in Formulation CDMO Services Business (2019-2024)
11.23.5 Viva Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Medicilon
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Zhejiang Jiuzhou Pharmaceutical
Sinopep
Frontier Biotechnologies
JYMed
Chengdu Shengnuo Biotechnology
Shanghai Soho-Yiming Pharmaceuticals
Chinese Peptide Company
Ambio Pharmaceuticals
Zhejiang Peptites Biotech
STA Pharmaceutical
Zhejiang Langhua Pharmaceutical
Viva Biotech
听
听
*If Applicable.
